K.L. Mettinger

2.1k total citations
45 papers, 1.6k citations indexed

About

K.L. Mettinger is a scholar working on Epidemiology, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, K.L. Mettinger has authored 45 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 12 papers in Infectious Diseases and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in K.L. Mettinger's work include Virus-based gene therapy research (12 papers), Viral gastroenteritis research and epidemiology (11 papers) and Cerebrovascular and Carotid Artery Diseases (8 papers). K.L. Mettinger is often cited by papers focused on Virus-based gene therapy research (12 papers), Viral gastroenteritis research and epidemiology (11 papers) and Cerebrovascular and Carotid Artery Diseases (8 papers). K.L. Mettinger collaborates with scholars based in Sweden, United States and United Kingdom. K.L. Mettinger's co-authors include K. Ericson, C.E. Söderström, K.G. Kjellin, Å Sidén, Matt Coffey, Kevin J. Harrington, Katie Twigger, Stephan Rössner, Victoria Roulstone and George M. Gill and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

K.L. Mettinger

42 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K.L. Mettinger Sweden 20 495 462 452 297 237 45 1.6k
Kohei Hashizume Japan 23 341 0.7× 326 0.7× 198 0.4× 916 3.1× 92 0.4× 107 2.5k
Betty Giannias Canada 17 913 1.8× 315 0.7× 116 0.3× 630 2.1× 50 0.2× 30 2.8k
Paloma Martín Spain 25 712 1.4× 273 0.6× 107 0.2× 740 2.5× 83 0.4× 59 2.2k
G Wong Canada 18 820 1.7× 162 0.4× 334 0.7× 433 1.5× 44 0.2× 22 2.0k
Poonam Mannan United States 17 298 0.6× 261 0.6× 97 0.2× 442 1.5× 110 0.5× 22 2.0k
M A Moore United States 18 855 1.7× 186 0.4× 357 0.8× 400 1.3× 37 0.2× 37 2.3k
Borko Jovanovic United States 19 215 0.4× 221 0.5× 145 0.3× 179 0.6× 78 0.3× 34 1.5k
Sue Ellen Martin United States 22 326 0.7× 375 0.8× 106 0.2× 316 1.1× 51 0.2× 51 1.6k
E. Van Marck Belgium 23 695 1.4× 580 1.3× 80 0.2× 610 2.1× 63 0.3× 59 1.8k
Josef Friedl Austria 18 424 0.9× 107 0.2× 131 0.3× 414 1.4× 60 0.3× 44 1.6k

Countries citing papers authored by K.L. Mettinger

Since Specialization
Citations

This map shows the geographic impact of K.L. Mettinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.L. Mettinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.L. Mettinger more than expected).

Fields of papers citing papers by K.L. Mettinger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.L. Mettinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.L. Mettinger. The network helps show where K.L. Mettinger may publish in the future.

Co-authorship network of co-authors of K.L. Mettinger

This figure shows the co-authorship network connecting the top 25 collaborators of K.L. Mettinger. A scholar is included among the top collaborators of K.L. Mettinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.L. Mettinger. K.L. Mettinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mettinger, K.L., et al.. (2018). Exosomes, stem cells and microRNA : aging, cancer and age related disorders. Springer eBooks. 2 indexed citations
2.
Karapanagiotou, Eleni, Victoria Roulstone, Katie Twigger, et al.. (2012). Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Clinical Cancer Research. 18(7). 2080–2089. 151 indexed citations
3.
4.
Mukherji, Deborah, Matt Coffey, K.L. Mettinger, et al.. (2009). Results of a phase I study to evaluate the feasibility, safety, and biological effects of intravenous administration of wild-type reovirus with docetaxel to patients with advanced malignancies. Journal of Clinical Oncology. 27(15_suppl). e13524–e13524. 1 indexed citations
5.
Arkenau, Hendrik‐Tobias, JEFF EVANS, Patricia Roxburgh, et al.. (2009). A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer. Journal of Clinical Oncology. 27(15_suppl). 3584–3584. 2 indexed citations
6.
Soefje, Scott A., John Sarantopoulos, Kamalesh K. Sankhala, et al.. (2008). A phase II study of intravenous reolysin (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. Journal of Clinical Oncology. 26(15_suppl). 10568–10568. 8 indexed citations
7.
Vidal, Laura, Alan Melcher, Kate Newbold, et al.. (2007). A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN (R)) in combination with radiation in patients with advanced malignancies.. Molecular Cancer Therapeutics. 6. 5 indexed citations
8.
Baka, Sofia, Malcolm Ranson, Paul Lorigan, et al.. (2005). A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. European Journal of Cancer. 41(11). 1547–1550. 9 indexed citations
9.
Rivera, Edgardo, Debbie Frye, Nuhad K. Ibrahim, et al.. (2005). Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 57(4). 540–544. 4 indexed citations
10.
Jonge, Maja J.A. de, J P Droz, Luis Paz‐Ares, et al.. (2004). Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors. Investigational New Drugs. 22(3). 329–333. 6 indexed citations
11.
Saba, Hussain I., C Rosenfeld, Jean‐Pierre J. Issa, et al.. (2004). First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS).. Blood. 104(11). 67–67. 33 indexed citations
12.
Jacobs, Andrew, Howard A. Burris, Saul E. Rivkin, et al.. (2004). A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. Journal of Clinical Oncology. 22(14_suppl). 4013–4013. 33 indexed citations
13.
Tulpule, Anil, Jerome E. Groopman, M. Wayne Saville, et al.. (2002). Multicenter trial of low‐dose paclitaxel in patients with advanced AIDS‐related Kaposi sarcoma. Cancer. 95(1). 147–154. 110 indexed citations
14.
Clark, Wayne M., Bruce M. Coull, Barry Hendin, et al.. (1996). Randomized trial of cervene, a κ receptor-selective opioid antagonist, in acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases. 6(1). 35–40. 12 indexed citations
15.
Sredni, Benjamin, Michael Albeck, Uzi Gafter, et al.. (1996). The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models. International Journal of Cancer. 65(1). 97–103. 64 indexed citations
16.
Riekkinen, Paavo, et al.. (1996). Effects of Alzene and tacrine on water maze reference and working memory function in medial septal-lesioned rats. Brain Research. 714(1-2). 118–124. 3 indexed citations
17.
Mettinger, K.L., C.E. Söderström, & Erik Allander. (1984). Epidemiology of acute cerebrovascular disease before the age of 55 in the Stockholm County 1973-77: I. Incidence and mortality rates.. Stroke. 15(5). 795–801. 33 indexed citations
18.
Svensson, Jan, K.L. Mettinger, & Margareta Blombäck. (1983). Enteric-coated aspirin and cyclooxygenase inhibition. Thrombosis Research. 29(1). 99–102. 6 indexed citations
19.
20.
Guðmundsson, Gunnar, et al.. (1980). Isoelectric focusing of cerebrospinal fluid proteins in ischemic cerebrovascular disease. Journal of Neurology. 222(4). 227–234. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kohei Hashizume Breakdown of academic impact, for papers by Betty Giannias Breakdown of academic impact, for papers by Paloma Martín Breakdown of academic impact, for papers by G Wong Breakdown of academic impact, for papers by Poonam Mannan Breakdown of academic impact, for papers by M A Moore Breakdown of academic impact, for papers by Borko Jovanovic Breakdown of academic impact, for papers by Sue Ellen Martin Breakdown of academic impact, for papers by E. Van Marck Breakdown of academic impact, for papers by Josef Friedl
Rankless by CCL
2026